Pediatric-onset Inflammatory Bowel Disease Has Only a Modest Effect on Final Growth: A Report From the epi-IIRN.
Journal
Journal of pediatric gastroenterology and nutrition
ISSN: 1536-4801
Titre abrégé: J Pediatr Gastroenterol Nutr
Pays: United States
ID NLM: 8211545
Informations de publication
Date de publication:
01 08 2021
01 08 2021
Historique:
pubmed:
16
2
2021
medline:
15
10
2021
entrez:
15
2
2021
Statut:
ppublish
Résumé
The impact of pediatric-onset inflammatory bowel disease (IBD) on growth is debated. We aimed to investigate the effect of IBD on anthropometric measures at young adulthood. Children diagnosed with Crohn disease (CD) or ulcerative colitis (UC) (2005-2019) were identified in a national database along with matched non-IBD controls. Overall, 2229 IBD cases (68% CD) were matched to 4338 controls. Only females with CD differed in final height from controls (z scores: -0.37 ± 1.09 vs -0.25 ± 1.06, respectively; P = 0.01), corresponding to a mean difference of 0.7 ± 0.2 cm (all females) and 1.2 ± 0.3 cm in females diagnosed <14 years (P = 0.02). Final height was reduced in both sexes according to adjusted mean height difference analysis (-0.43 cm, 95% confidence interval -0.85 to -0.02; P = 0.04). This difference increased in patients with CD who underwent abdominal surgery (-0.91 cm, 95% confidence interval -1.39 to -0.42; P = 0.01). The proportion of patients with CD achieving final height z scores of -1 and zero differed significantly from controls for both males (71.1% and 34.8% vs 79.1% and 43.0%, respectively; P < 0.001) and females (67.7% and 30.4% vs 79.6%, and 43.3%, respectively; P < 0.001). Patients treated with anti-tumor necrosis factor agents during growth potential had similar height improvement to other regimens. Predominantly, patients with CD were leaner, with a greater proportion of subjects with underweight, compared with controls. In pediatric-onset IBD, absolute final height was modestly affected by females with CD. Nevertheless, greater proportions of both sexes with early diagnosis of CD failed to achieve normal final height, compared with controls.
Identifiants
pubmed: 33587410
doi: 10.1097/MPG.0000000000003072
pii: 00005176-202108000-00018
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
223-230Informations de copyright
Copyright © 2021 by European Society for Pediatric Gastroenterology, Hepatology, and Nutrition and North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest.
Références
Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002; 347:417–429.
Heuschkel R, Salvestrini C, Beattie RM, et al. Guidelines for the management of growth failure in childhood inflammatory bowel disease. Inflamm Bowel Dis 2008; 14:839–849.
Motil KJ, Grand RJ, Davis-Kraft L, et al. Growth failure in children with inflammatory bowel disease: a prospective study. Gastroenterology 1993; 105:681–691.
Assa A, Shamir R. Impact of therapeutic strategies on growth in pediatric inflammatory bowel disease. J Clin Cell Immunol 2014; 5:235.
Hildebrand H, Karlberg J, Kristiansson B. Longitudinal growth in children and adolescents with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 1994; 18:165–173.
Wine E, Reif SS, Leshinsky-Silver E, et al. Pediatric Crohn's disease and growth retardation: the role of genotype, phenotype, and disease severity. Pediatrics 2004; 114:1281–1286.
Markowitz J, Grancher K, Rosa J, et al. Growth failure in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr 1993; 16:373–380.
Vasseur F, Gower-Rousseau C, Vernier-Massouille G, et al. Nutritional status and growth in pediatric Crohn's disease: a population-based study. Am J Gastroenterol 2010; 105:1893–1900.
Pfefferkorn M, Burke G, Griffiths A, et al. Growth abnormalities persist in newly diagnosed children with Crohn disease despite current treatment paradigms. J Pediatr Gastroenterol Nutr 2009; 48:168–174.
Sawczenko A, Ballinger AB, Savage MO, et al. Clinical features affecting final adult height in patients with pediatric-onset Crohn's disease. Pediatrics 2006; 118:124–129.
Herzog D, Fournier N, Buehr P, et al. Early-onset Crohn's disease is a risk factor for smaller final height. Eur J Gastroenterol Hepatol 2014; 26:1234–1239.
Ghersin I, Khateeb N, Katz LH, et al. Anthropometric measures in adolescents with inflammatory bowel disease: a population-based study. Inflamm Bowel Dis 2019; 25:1061–1065.
Mouratidou N, Malmborg P, Sachs MC, et al. Adult height in patients with childhood-onset inflammatory bowel disease: a nationwide population-based cohort study. Aliment Pharmacol Ther 2020; 51:789–800.
Friedman MY, Leventer-Roberts M, Rosenblum J, et al. Development and validation of novel algorithms to identify patients with inflammatory bowel diseases in Israel: an epi-IIRN group study. Clin Epidemiol 2018; 10:671–681.
Yerushalmy-Feler A, Galai T, Moran-Lev H, et al. BMI in the lower and upper quartiles at diagnosis and at 1-year follow-up is significantly associated with higher risk of disease exacerbation in pediatric inflammatory bowel disease. Eur J Pediatr 2021; 180:21–29.
Lane ER, Lee D, Suskind DL. Dietary therapies in pediatric inflammatory bowel disease: an evolving inflammatory bowel disease paradigm. Gastroenterol Clin North Am 2017; 46:731–744.
Batra S, Conklin LS. Therapeutics for inflammatory bowel diseases in children and adolescents: a focus on biologics and an individualized treatment paradigm. Handb Exp Pharmacol 2020; 261:363–375.
Guilcher K, Fournier N, Schoepfer A, et al. Swiss IBD Cohort Study. Change of treatment modalities over the last 10 years in pediatric patients with inflammatory bowel disease in Switzerland. Eur J Gastroenterol Hepatol 2018; 30:1159–1167.
Laakso S, Valta H, Verkasalo M, et al. Compromised peak bone mass in patients with inflammatory bowel disease—a prospective study. J Pediatr 2014; 164:1436–1443.
Gupta N, Liu C, King E, et al. ImproveCareNow Network. Continued statural growth in older adolescents and young adults with Crohn's disease and ulcerative colitis beyond the time of expected growth plate closure. Inflamm Bowel Dis 2020; 26:1880–1889.
Lee GJ, Kappelman MD, Boyle B, et al. Role of sex in the treatment and clinical outcomes of pediatric patients with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2012; 55:701–706.
Gupta N, Lustig RH, Kohn MA, et al. Sex differences in statural growth impairment in Crohn's disease: role of IGF-1. Inflamm Bowel Dis 2011; 17:2318–2325.
Gupta N, Bostrom AG, Kirschner BS, et al. Gender differences in presentation and course of disease in pediatric patients with Crohn disease. Pediatrics 2007; 120:e1418–e1425.
Malik S, Wong SC, Bishop J, et al. Improvement in growth of children with Crohn disease following anti-TNF-α therapy can be independent of pubertal progress and glucocorticoid reduction. J Pediatr Gastroenterol Nutr 2011; 52:31–37.
Walters TD, Kim MO, Denson Griffiths AM, et al. PRO-KIIDS Research Group. Increased effectiveness of early therapy with anti-tumor necrosis factor-α vs an immunomodulator in children with Crohn's disease. Gastroenterology 2014; 146:383–391.
Pichler J, Hanslik A, Huber WD, et al. Paediatric patients with inflammatory bowel disease who received infliximab experienced improved growth and bone health. Acta Paediatr 2014; 103:e69–e75.
Matar M, Shamir R, Lev-Zion R, et al. The effect of adalimumab treatment on linear growth in children with Crohn disease: a post-hoc analysis of the PAILOT randomized control trial. J Pediatr Gastroenterol Nutr 2020; 71:237–242.
Thangarajah D, Hyde MJ, Konteti VK, et al. Systematic review: body composition in children with inflammatory bowel disease. Aliment Pharmacol Ther 2015; 42:142–157.
Chouliaras G, Mantzou A, Margoni D, et al. Body height in paediatric inflammatory bowel diseases: a structural equation model analysis. Eur J Clin Invest 2018; 48:e12969.
Wong K, Isaac DM, Wine E. Growth delay in inflammatory bowel diseases: significance, causes, and management. Dig Dis Sci 2021; [Epub ahead of print].
Sanderson IR. Growth problems in children with IBD. Nat Rev Gastroenterol Hepatol 2014; 11:601–610.
Cohen-Dolev N, Sladek M, Hussey S, et al. Differences in outcomes over time with exclusive enteral nutrition compared with steroids in children with mild to moderate Crohn's disease: results from the Growth CD study. J Crohns Colitis 2018; 12:306–312.
Brückner A, Werkstetter KJ, Frivolt K, et al. Partial enteral nutrition has no benefit on bone health but improves growth in paediatric patients with quiescent or mild Crohn's disease. Clin Nutr 2020; 39:3786–3796.